Back to Search Start Over

Anacetrapib as a potential cardioprotective strategy

Anacetrapib as a potential cardioprotective strategy

Authors :
Belinda A. Di Bartolo
Stephen J. Nicholls
Source :
Drug Design, Development and Therapy
Publication Year :
2017
Publisher :
Informa UK Limited, 2017.

Abstract

Cholesteryl ester transfer protein (CETP) facilitates movement of esterified cholesterol between high-density lipoproteins (HDLs) and apolipoprotein B-containing lipoproteins. By virtue of their ability to raise HDL cholesterol and lower low-density lipoprotein cholesterol, pharmacological inhibitors of CETP have received considerable attention as potential new agents in cardiovascular prevention. While early studies of CETP inhibitors have demonstrated a lack of clinical efficacy and potential toxicity, development of the potent CETP inhibitor, anacetrapib, has moved forward, with emerging evidence suggesting a role in reducing cardiovascular events. The experience with anacetrapib and its potential for use in clinical practice are reviewed here.

Details

ISSN :
11778881
Volume :
11
Database :
OpenAIRE
Journal :
Drug Design, Development and Therapy
Accession number :
edsair.doi.dedup.....e2c0768094f3b6a7109350e629897507
Full Text :
https://doi.org/10.2147/dddt.s114104